Company Overview and News

2
Rhythm Pharmaceuticals Diversifies As A Major Catalyst Approaches

2018-04-09 seekingalpha
Rhythm Pharmaceuticals Inc (RYTM) is a biopharmaceutical company, developing drugs for rare genetic disorders of obesity, which went public via IPO in October, 2017.
Upvote Downvote

 
DBV Technologies :Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social

2018-04-05 globenewswire
Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social
Upvote Downvote

 
DBV Technologies: Monthly information regarding the total number of voting rights and total number of shares of the Company

2018-04-05 globenewswire
Monthly information regarding the total number of voting rights and total number of shares of the Company
Upvote Downvote

 
DBV Technologies invitée à participer à la 11ème Life Sciences Conference de Kempen

2018-04-03 globenewswire
DBV Technologies (Euronext : DBV - ISIN : FR0010417345 - Nasdaq : DBVT), une société biopharmaceutique française, annonce aujourd'hui que Susanna Mesa, Chief Business Officer, tiendra des rendez-vous investisseurs lors de la 11ème Life Sciences Conference de Kempen, le mercredi 18 avril 2018, dans les locaux de Kempen & Co à Amsterdam, aux Pays-Bas.
Upvote Downvote

 
DBV Technologies to Attend the 11th Kempen Life Sciences Conference

2018-04-03 globenewswire
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced that Susanna Mesa, Chief Business Officer, will host investor meetings during the 11th Kempen Life Sciences Conference on Wednesday, April 18, 2018 at the Kempen & Co offices in Amsterdam, Netherlands.
Upvote Downvote

 
DBV Technologies Announces Closing of Underwriters' Option to Purchase Additional Shares in Global Offering

2018-03-26 globenewswire
DBV Technologies (the "Company") (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the issuance and the settlement and delivery of an aggregate of an additional 529,162 ordinary shares, including 208,802 ordinary shares in the form of 417,604 ADSs, on the same terms and conditions as the securities previously sold in the global offering, pursuant to the exercise of the underwriters' option to purchase additional ordinary shares, including in the form of American Depositary Shares (ADSs), in the Company's previously announced global offering (the "Option Closing").
Upvote Downvote

 
DBV Technologies annonce le règlement-livraison des actions ordinaires supplémentaires au titre de l'exercice de la totalité de l'option de surallocation dans le cadre de son offre globale

2018-03-26 globenewswire
DBV Technologies annonce le règlement-livraison des actions ordinaires supplémentaires au titre de l'exercice de la totalité de l'option de surallocation dans le cadre de son offre globale
Upvote Downvote

 
DBV Technologies Announces Pricing of $150.0 million (€122.5 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares

2018-03-21 globenewswire
DBV Technologies Announces Pricing of $150.0 million (€122.5 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares
Upvote Downvote

1
DBV Technologies annonce le prix de son offre globale d'actions ordinaires, pouvant prendre la forme d'American Depositary Shares, pour un montant total de 150 millions de dollars américains

2018-03-21 globenewswire
DBV Technologies annonce le prix de son offre globale d'actions ordinaires, pouvant prendre la forme d'American Depositary Shares, pour un montant total de 150 millions de dollars américains (soit 122,5 millions d'euros)
Upvote Downvote

 
DBV Technologies Annonce le lancement d'une offre globale d'actions ordinaires, pouvant prendre la forme d'American Depositary Shares

2018-03-20 globenewswire
DBV Technologies Annonce le lancement d'une offre globale d'actions ordinaires, pouvant prendre la forme d'American Depositary Shares
Upvote Downvote

 
BRIEF-DBV Technologies ‍Announces Intention To Issue And Sell Up To $150 Mln Of New Ordinary Shares​

2018-03-20 reuters
* DBV TECHNOLOGIES ANNOUNCES THE LAUNCH OF A PROPOSED GLOBAL OFFERING OF ORDINARY SHARES, WHICH MAY BE IN THE FORM OF AMERICAN DEPOSITARY SHARES
Upvote Downvote

 
DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares

2018-03-20 globenewswire
DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares
Upvote Downvote

 
DBV Technologies Publie son Document de Référence 2017 et son «Form 20-F» américain

2018-03-16 globenewswire
DBV Technologies (Euronext : DBV - ISIN : FR0010417345 - Nasdaq : DBVT), une société biopharmaceutique, annonce aujourd'hui que son Document de Référence 2017 a été déposé auprès de l'Autorité des Marchés Financiers (AMF) en France et son « Form 20-F » auprès de la « Securities and Exchange Commission » (SEC) aux Etats-Unis.
Upvote Downvote

 
DBV Technologies Announces Filing of 2017 "Document de Référence" and 2017 Annual Report on Form 20-F

2018-03-16 globenewswire
DBV Technologies Announces Filing of 2017 "Document de Référence" and 2017 Annual Report on Form 20-F
Upvote Downvote

 
U.S. Biotech/Pharma Sector Daily Observations Letter: February 26, 2018

2018-02-27 seekingalpha
The broad market seems to be on its way to make new highs but a small 2-3% pullback may be due this week.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...